Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...

Related Keywords

United States ,Stacy Nartker ,Wildon Farwell ,Amy Reilly ,John Cox ,Exchange Commission ,Nasdaq ,Drug Administration ,Facebook ,Linkedin ,Myotonic Dystrophy Health Index ,European Medicines Agency ,Dyne Therapeutics Inc ,Dose Dependent ,Mean Splicing Correction Across All Patients ,Muscle Strength ,Timed Function Tests ,Reported Outcomes ,Mean Unadjusted ,Mean Muscle Adjusted ,Dystrophin Expression ,Cohort Administered Monthly ,Higher Level ,Dystrophin Than Reported ,Weekly Administered Standard ,Functional Improvement ,Run Time ,Stride Velocity ,Safety Profiles ,Enrollment Complete ,Recent Regulatory Interactions ,Pursue Expedited Approvals ,Both Programs ,Registrational Pathways Expected ,Investor Event Today ,Timed Assessments ,Quantitative Myometry Testing ,Run Test ,Dystrophy Health Index ,Dystrophy Type ,Participation Scale ,North Star Ambulatory Assessment ,Drug Evaluation ,Myotonic Dystrophy Type ,Duchenne Muscular Dystrophy ,Private Securities Litigation Reform Act ,Clinical Update ,